Omeros (OMER) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares.
View OMER analyst ratings or view top-rated stocks.

3 brokers have issued twelve-month price objectives for Omeros' shares. Their OMER share price forecasts range from $3.00 to $13.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 174.0% from the stock's current price.
View analysts price targets for OMER or view top-rated stocks among Wall Street analysts.

Omeros' stock was trading at $2.26 at the start of the year. Since then, OMER shares have increased by 29.2% and is now trading at $2.92.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our OMER earnings forecast.

Omeros Co. (NASDAQ:OMER) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.10.

17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX).

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of OMER stock can currently be purchased for approximately $2.92.

Omeros (NASDAQ:OMER) has a market capitalization of $183.55 million and generates $73.81 million in revenue each year. The biopharmaceutical company earns $47.42 million in net income (profit) each year or $0.64 on an earnings per share basis.

The company employs 196 workers across the globe.

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The official website for the company is www.omeros.com. The biopharmaceutical company can be reached via phone at (206) 676-5000, via email at ir@omeros.com, or via fax at 206-676-5005.